This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
by Moumi Mondal
Boston Scientific tops Q4 estimates, but shares sink on supply woes and EP losses. Can strong growth drivers fuel a 2026 rebound?
BSXNegative Net Change SYKPositive Net Change EWPositive Net Change
medical medical-devices
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
by Zacks Equity Research
West Pharmaceutical beats Q4 EPS and revenue estimates as proprietary products drive growth, while shares jump nearly 3.6% premarket on upbeat 2026 outlook.
ISRGPositive Net Change MASINegative Net Change MMSIPositive Net Change WSTNegative Net Change
earnings medical medical-devices
Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care
by Zacks Equity Research
SYK launches the T2 Alpha Humerus Nailing System to enhance complex fracture care, boosting procedural efficiency and strengthening its trauma portfolio.
SYKPositive Net Change ISRGPositive Net Change ATRCPositive Net Change GEHCPositive Net Change
medical medical-devices
BAX Stock Falls Following Q4 Earnings Miss, Margins Contract
by Zacks Equity Research
Baxter International misses Q4 EPS estimates as margins shrink, even as revenues top forecasts; shares slide 12.5% on weak 2026 guidance.
BAXPositive Net Change ISRGPositive Net Change DVAPositive Net Change CAHPositive Net Change
earnings medical medical-devices
INSP Stock Falls Despite Q4 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
INSP beats Q4 estimates with EPS up 43% and wider margins, but shares tumble 8.7% after a lower 2026 revenue outlook.
ISRGPositive Net Change DVAPositive Net Change CAHPositive Net Change INSPNegative Net Change
earnings medical medical-devices
AVTR Stock Plunges Despite Q4 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Avantor stock sinks 13% as Q4 earnings beat estimates, but revenues slip, margins contract and 2026 outlook signals more pressure ahead.
DVAPositive Net Change CAHPositive Net Change AVTRNegative Net Change DOCSPositive Net Change
earnings medical medical-devices
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
by Debanjana Dey
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.
MEDPositive Net Change TDOCNegative Net Change HIMSNegative Net Change
medical medical-devices
QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down
by Zacks Equity Research
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
DVAPositive Net Change CAHPositive Net Change QDELNegative Net Change DOCSPositive Net Change
earnings medical medical-devices
Envista Stock Rises Post Q4 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
NVST shares jump 22% after Q4 EPS and revenue beat, with profits up 58% and double-digit segment growth despite gross margin pressure.
ISRGPositive Net Change ALGNPositive Net Change CAHPositive Net Change NVSTPositive Net Change
earnings medical medical-devices
PBH's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Up
by Zacks Equity Research
Prestige Consumer stock ticks higher as Q3 revenues top estimates, but EPS slips 7% and misses forecasts despite margin expansion.
ISRGPositive Net Change ALGNPositive Net Change CAHPositive Net Change PBHPositive Net Change
earnings medical medical-devices